PERRIGO COMPANY PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.94 USD | +2.14% |
|
+6.25% | -0.75% |
| Apr. 25 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
| Apr. 25 | Perrigo Receives Binding Offer to Sell HRA Pharma Rare Diseases Business for Up to $295 Million | MT |
Financials (USD)
| Sales 2024 * | 4.66B | Sales 2025 * | 4.86B | Capitalization | 4.24B |
|---|---|---|---|---|---|
| Net income 2024 * | -51M | Net income 2025 * | 101M | EV / Sales 2024 * | 1.59 x |
| Net Debt 2024 * | 3.18B | Net Debt 2025 * | 3.01B | EV / Sales 2025 * | 1.49 x |
| P/E ratio 2024 * |
-83.8
x | P/E ratio 2025 * |
55.8
x | Employees | 9,140 |
| Yield 2024 * |
3.52% | Yield 2025 * |
3.75% | Free-Float | 99.69% |
More Fundamentals
* Assessed data
More news
Latest transcript on Perrigo Company plc
More recommendations
More press releases
More news
| 1 day | +2.14% | ||
| 1 week | +6.25% | ||
| Current month | -0.78% | ||
| 1 month | +1.53% | ||
| 3 months | -3.71% | ||
| 6 months | +18.38% | ||
| Current year | -0.75% |
1 week
30.01
32.29
1 month
29.7932.46
Current year
25.7734.60
1 year
25.7740.28
3 years
25.7750.90
5 years
25.7763.86
10 years
25.77215.73
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 23-06-29 | |
Eduardo Bezerra
DFI | Director of Finance/CFO | 49 | 22-05-15 |
Alison Ives
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Orlando Ashford
CHM | Chairman | 55 | 20-12-14 |
Jeffrey Kindler
BRD | Director/Board Member | 68 | 17-02-05 |
Bradley Alford
BRD | Director/Board Member | 67 | 17-02-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 18.63% | 13 M€ | -.--% | ||
| 15.31% | 215 M€ | +10.68% | - | |
| 0.66% | 8 M€ | +5.48% | - | |
| 0.46% | 2 M€ | +6.77% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 31.27 | +0.13% | 1,084,163 |
| 24-04-24 | 31.23 | +2.43% | 963,661 |
| 24-04-23 | 30.49 | +1.43% | 1,113,011 |
| 24-04-22 | 30.06 | -2.40% | 1,415,881 |
| 24-04-19 | 30.8 | +2.87% | 1,168,219 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotes
Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others.
Sector
Pharmaceuticals
Calendar
2024-05-02
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
31.27
USD
Average target price
39.72
USD
Spread / Average Target
+27.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.75% | 4.24B | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.26% | 144B |
- Stock Market
- Equities
- PRGO Stock
